Medical technology company Soliton has developed a second-generation acoustic shockwave device with the aim of treating cellulite reduction and tattoo removal.
The device will be will be used in clinical trials and will require premarket clearance by the FDA prior to commercialisation.
Dr. Chris Capelli, CEO of Soliton, said: “This is a tremendous step forward for our technology that allows us to target not only tattoo removal but also cellulite reduction. Our second generation device is now a platform technology that provides healthcare professionals with the flexibility to potentially to treat multiple indications with a single device by simply changing the replaceable single treatment cartridge.”
The Rapid Acoustic Pulse (‘RAP”) device may be capable of treating both tattoos and cellulite conditions. In order to properly target cellulite, the device needed to be capable of running a specifically designed cartridge which required a runtime 20 times longer than the tattoo removal cartridge and a customised waveform which would penetrate deeper into the skin.
